6-APDB
6-(2-aminopropyl)-2,3-dihydrobenzofuran
Lethal interactions
Specific substances
- Tramadollethal
By drug class
- MAOIslethal6 mechanismsconfidence high
Dangerous interactions
34 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
Cardiovascular
- cardiac valve diseaseabsolute
Pre-existing cardiac valve disease is an absolute contraindication due to 6-APDB's confirmed 5-HT2B agonism, which directly promotes valve fibrosis through TGFβ-dependent mitogenic signaling.
- pulmonary arterial hypertensionabsolute
Pulmonary arterial hypertension is an absolute contraindication. 5-HT2B activation promotes pulmonary vascular remodeling.
- uncontrolled hypertensionrelative
Uncontrolled hypertension is a relative contraindication due to norepinephrine-releasing activity producing additional cardiovascular stress.
Neurological
- epilepsyrelative
Epilepsy or seizure disorders are a relative contraindication. Monoamine release and stimulant effects may lower seizure threshold.
Psychiatric
- bipolar disorderrelative
Bipolar disorder is a relative contraindication. Stimulant and serotonergic effects may trigger manic or mixed episodes.
- psychotic disordersrelative
Personal or family history of psychotic disorders is a relative contraindication. Monoamine release may trigger psychotic episodes in predisposed individuals.
Hepatic
- hepatic impairmentrelative
Hepatic impairment is a relative contraindication. Reduced CYP enzyme activity may result in higher and more prolonged drug exposure.
Pregnancy & Breastfeeding
- pregnancy and breastfeedingabsolute
Pregnancy and breastfeeding are absolute contraindications. No reproductive safety data exist for 6-APDB; class-level risks from monoamine release apply.